Autor: "Grinspan, A." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Fecal microbiota transplantation may reduce the mortality of patients with severe and fulminant Clostridioides difficile infection compared to standard-of-care antibiotics in a community hospital.
Autorzy:: Mironova M; Division of Internal Medicine, Capital Health, Trenton, New Jersey, USA.
Ehrlich AC; Section of Gastroenterology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.
Grinspan A; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Protano MA; Division of Gastroenterology, Capital Health, Pennington, New Jersey, USA.; Pokaż więcej
Źródło:: Journal of digestive diseases [J Dig Dis] 2022 Aug; Vol. 23 (8-9), pp. 500-505. Date of Electronic Publication: 2022 Oct 31.
Typ publikacji:: Journal Article
MeSH Terms:: Clostridioides difficile*
Clostridium Infections*/drug therapy
Humans ; Fecal Microbiota Transplantation ; Anti-Bacterial Agents/therapeutic use ; Hospitals, Community ; Treatment Outcome ; Recurrence

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Autorzy:: Kolitz S; Immuneering Corporation, Cambridge, MA, USA.
Hasson T; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Towfic F; Immuneering Corporation, Cambridge, MA, USA.
Funt JM; Immuneering Corporation, Cambridge, MA, USA.
Bakshi S; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Fowler KD; Immuneering Corporation, Cambridge, MA, USA.
Laifenfeld D; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Grinspan A; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Artyomov MN; Immuneering Corporation, Cambridge, MA, USA.
Birnberg T; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Schwartz R; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Komlosh A; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Hayardeny L; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Ladkani D; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Hayden MR; Teva Pharmaceutical Industries, Petach Tikva, Israel.
Zeskind B; Immuneering Corporation, Cambridge, MA, USA.
Grossman I; Teva Pharmaceutical Industries, Petach Tikva, Israel.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2015 May 22; Vol. 5, pp. 10191. Date of Electronic Publication: 2015 May 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Glatiramer Acetate/*pharmacology
Transcriptome/*drug effects
Cell Line ; Chemokines/genetics ; Chemokines/metabolism ; Humans ; Matrix Metalloproteinases/genetics ; Matrix Metalloproteinases/metabolism ; Monocytes/cytology ; Monocytes/drug effects ; Monocytes/metabolism ; RNA, Messenger/metabolism ; Real-Time Polymerase Chain Reaction ; Up-Regulation/drug effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
Autorzy:: Agius M; Department of Neurology, University of California Davis, Davis, CA, USA; Veteran's Affairs Northern California Health Care System, Mather, CA, USA.
Meng X
Chin P
Grinspan A
Hashmonay R; Pokaż więcej
Źródło:: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2014 May; Vol. 20 (5), pp. 446-51. Date of Electronic Publication: 2014 Mar 31.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Immunosuppressive Agents/*therapeutic use
Multiple Sclerosis/*drug therapy
Propylene Glycols/*therapeutic use
Sphingosine/*analogs & derivatives
Adult ; Disease Progression ; Female ; Fingolimod Hydrochloride ; Gadolinium ; Humans ; Immunologic Factors/therapeutic use ; Interferon beta-1a ; Interferon-beta/therapeutic use ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging/methods ; Male ; Multiple Sclerosis/pathology ; Secondary Prevention ; Sphingosine/therapeutic use ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Grinspan, A."" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język